Hillhurst Biopharmaceuticals, Inc.

This study is testing a new liquid medication called HBI-002, which contains a very low dose of carbon monoxide. It aims to see if taking it daily for two weeks is safe and how the body processes it in people with Parkinson's disease. The trial will involve 36 participants who wi…